DJIA 16,374.76 23.38 0.14%
NASDAQ 4,733.50 -16.48 -0.35%
S&P 500 1,951.13 2.27 0.12%
market minute promo

39.13 1.06 (2.78%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ACAD $39.13 2.78%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $42.18
Previous Close $38.07
Daily Range $38.40 - $43.50
52-Week Range $22.04 - $51.99
Market Cap $3.9B
P/E Ratio -28.41
Dividend (Yield) $0.00 (0.0%)
Volume 3,618,579
Average Daily Volume 1,254,061
Current FY EPS -$1.49

Sector

Healthcare

Industry

Drug Makers

ACADIA Pharmaceuticals, Inc. (ACAD) Description

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. Website: http://www.acadia-pharm.com/

News & Commentary

Why Parkinson's Disease-Focused ACADIA Pharmaceuticals is Soaring Today

The company officially submitted a New Drug Application to the FDA for its lead compound Nuplazid, and investors cheered the news.

Acadia Pharmaceuticals (ACAD) Stock Climbs on Drug Application for Parkinson's Treatment

Morning Market Gainers

Benzinga's Top #PreMarket Gainers

Why Piper Jaffray Is Upgrading Acadia Pharmaceuticals After A 25% Decline

Top Analyst Upgrades and Downgrades: Amazon, Monsanto, Schlumberger, SolarCity, Western Digital, Yel

Top Analyst Upgrades and Downgrades: Amazon, Monsanto, Schlumberger, SolarCity, Western Digital, Yelp, Abercrombie and Many More

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Acadia Pharmaceuticals (ACAD) Shares Cross Below 200 DMA

Why ACADIA Pharmaceuticals (ACAD) Could Be Positioned for a Slump

3 Small-Cap Biopharma Stocks I'd Never Short

Bellicum Pharmaceuticals, Exelixis, and Sarepta Therapeutics are three small-cap biopharma stocks that carry too much risk to short. Here's why.

See More ACAD News...

ACAD's Top Competitors

ACAD $39.13 (2.78%)
Current stock: ACAD
AMGN $149.23 (-2.01%)
Current stock: AMGN
GILD $101.91 (-2.26%)
Current stock: GILD
BIIB $301.63 (-0.85%)
Current stock: BIIB